Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case reportYong Zhang, Guiyun Cui, Ying Sheng et al.|Journal of Neurology|2024Cited by 28
Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti‐<scp>BCMA CAR</scp> T‐cell‐based therapyYuekun Qi, Jiang Cao, Hujun Li et al.|American Journal of Hematology|2024Cited by 21
In vivo manufacture and manipulation of CAR-T cells for better druggabilityRui Hou, Ming Shi, Xiaoxue Zhang et al.|Cancer and Metastasis Reviews|2024Cited by 18
Anti-BCMA/CD19 CAR T cell therapy in patients with refractory generalized myasthenia gravis: a single-arm, phase 1 trialYong Zhang, Ming Shi, Dan Liu et al.|EClinicalMedicine|2025Cited by 12
CRISPR screens in mechanism and target discovery for AMLLin Tian, Ming Shi, Dan Liu et al.|Heliyon|2024Cited by 10